富马酸吉特替尼

Description

Gilteritinib Fumarate · CAS 1254053-84-3 · C62H92N16O10. UNII 5RZZ0Z1GJT.

Identification

CAS Registry Number	1254053-84-3
PubChem CID	76970819
Molecular formula	C62H92N16O10
IUPAC name	(E)-but-2-enedioic acid;bis(6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide)
UNII (FDA)	5RZZ0Z1GJT

Computed Descriptors

Molecular Weight	1221.5
Hydrogen Bond Donor Count	8
Hydrogen Bond Acceptor Count	24
Rotatable Bond Count	20
Exact Mass	1220.71823320
Monoisotopic Mass	1220.71823320
Topological Polar Surface Area	317
Heavy Atom Count	88
Formal Charge	0
Complexity	904

Documented Uses

• Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors
• Gilteritinib fumarate is approved to treat:
• • Acute myeloid leukemia that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults whose cancer has a mutation in the FLT3 gene.
• Gilteritinib fumarate is also being studied in the treatment of other types of cancer.

Synonyms

Gilteritinib fumarate; Gilteritinib hemifumarate; 1254053-84-3; ASP-2215 hemifumarate; ASP2215 hemifumarate; UNII-5RZZ0Z1GJT; 5RZZ0Z1GJT; Xospata; RefChem:58109; Gilteritinib fumarate [USAN]; GILTERITINIB FUMARATE [JAN]; MFCD28386208; Xospata (TN); 1254053-84-3 (hemifumarate); CHEMBL3301603; SCHEMBL21819929

Frequently Asked Questions

What are the CAS number and molecular formula of Gilteritinib Fumarate?

CAS 1254053-84-3; molecular formula C62H92N16O10; molecular weight — g/mol.

What other names is Gilteritinib Fumarate known by?

Gilteritinib fumarate, Gilteritinib hemifumarate, 1254053-84-3, ASP-2215 hemifumarate, ASP2215 hemifumarate, UNII-5RZZ0Z1GJT.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.